Search This Blog

Wednesday, July 3, 2019

Ligand Pharma out-licenses OmniAb platform to Millennium Pharma

Ligand Pharmaceuticals (NASDAQ:LGND) has entered into an OmniAb commercial platform license and services agreement with Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical (NYSE:TAK).
Under the license, Takeda and its affiliates will be able to use OmniAb platform rodents and birds in campaigns to discover antibodies as well as therapies using engineered cells and OmniAb-derived binders.
LGND is receiving annual access fees and will receive milestone payments and tiered single-digit royalty payments for each product incorporating or delivering an OmniAb antibody and any scientific services provided. Takeda will be responsible for all costs related to the programs.
Posted by at No comments:

RedHill Bio’s Talicia nabs accelerated review status

The FDA has accepted for review RedHill Biopharma’s (NASDAQ:RDHL) NDA for Talicia (RHB-105) for H. pylori infection. The NDA has also been granted Priority Review designation.
PDUFA action date is November 2, 2019.
If approved, Talicia would be eligible for eight years of U.S. market exclusivity.
Talicia (RHB-105) is an oral capsule combination of two antibiotics, rifabutin, and amoxicillin, and a proton pump inhibitor, omeprazole.
Shares are up 3% premarket.
Posted by at No comments:

Centene boosts stake on Spanish healthcare provider to 90%

Centene (NYSE:CNC) has increased its stake in València, Spain-based Ribera Salud Group to 90% (from 50%) via a transaction with partner Banco Sabadell.
Posted by at No comments:

Nu Skin -6% after USANA warning

Nu Skin (NUS -5.7%) falls sharply after traders latch on to the weak guidance posted by USANA Health Sciences yesterday after the market closed.
Jefferies warns that the comments from USANA management on China don’t bode well for Nu Skin.
Shares of Nu Skin are only about a dollar away from the 52-week low of $44.36.
Posted by at No comments:

Shire prevails in Mydayis patent challenge

Takeda’s (TAK +0.2%) Shire plc is the winner of a challenge to two patents protecting long-acting ADHD med Mydayis by a would-be generic competitor. The USPTO’s Patent Trial and Appeal Board ruled that KVK-Tech failed to prove that the patents, covering the method of releasing the drug, are invalid.
Posted by at No comments:

Allergan sues Ajanta over generic of high blood pressure drug

Allergan (NYSE:AGN) alleges that a proposed generic version of a treatment for high blood pressure from Ajanta infringes on its patent for Bystolic, Bloomberg reports, citing the complaint filed in federal court in Wilmington, DE.
The company is seeking a court order to halt copies until the patent expires and to collect payment if copies are made before the patent expiration.
Patent expires in December 2021.
Allergan’s U.S. sales of Bystolic were $128.3M during the first three months of 2019, down 3.4% from the same period a year earlier.
Posted by at No comments:

Karyopharm prices Xpovio at $22K per month

During its conference call this afternoon, Karyopharm Therapeutics (KPTI+37.3%) stated that the wholesale (WAC) price of XPOVIO (selinexor) will be $22K per month.
The multiple myeloma med will be distributed through specialty pharmacies, including units of AmerisourceBergen and McKesson.
The company’s marketing application in Europe is currently under EMA review. Management expects conditional approval by year-end.
Applications in diffuse large B-cell lymphoma are next up.
Posted by at No comments:
Subscribe to: Comments (Atom)